Nicholas Investment Partners LP Has $4.04 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Nicholas Investment Partners LP trimmed its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENEFree Report) by 89.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,752 shares of the biopharmaceutical company’s stock after selling 766,695 shares during the period. Nicholas Investment Partners LP owned about 0.13% of Xenon Pharmaceuticals worth $4,042,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Braidwell LP increased its holdings in Xenon Pharmaceuticals by 15.0% in the third quarter. Braidwell LP now owns 2,103,396 shares of the biopharmaceutical company’s stock valued at $71,852,000 after purchasing an additional 275,043 shares during the period. Wellington Management Group LLP grew its holdings in Xenon Pharmaceuticals by 64.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,728,108 shares of the biopharmaceutical company’s stock worth $59,032,000 after acquiring an additional 677,057 shares during the period. TimesSquare Capital Management LLC grew its holdings in Xenon Pharmaceuticals by 34.4% during the 4th quarter. TimesSquare Capital Management LLC now owns 793,954 shares of the biopharmaceutical company’s stock worth $36,570,000 after acquiring an additional 203,379 shares during the period. Invesco Ltd. grew its holdings in Xenon Pharmaceuticals by 2.3% during the 3rd quarter. Invesco Ltd. now owns 716,303 shares of the biopharmaceutical company’s stock worth $24,469,000 after acquiring an additional 16,318 shares during the period. Finally, First Turn Management LLC acquired a new stake in Xenon Pharmaceuticals during the 4th quarter worth about $31,339,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $601,640.00. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at approximately $92,560. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $601,640.00. Following the transaction, the director now owns 2,000 shares of the company’s stock, valued at approximately $92,560. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sherrington Robin sold 7,137 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the sale, the executive vice president now directly owns 8,398 shares in the company, valued at approximately $388,659.44. The disclosure for this sale can be found here. Insiders own 5.43% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on XENE shares. Wedbush decreased their price target on Xenon Pharmaceuticals from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, April 10th. Royal Bank of Canada reduced their target price on Xenon Pharmaceuticals from $56.00 to $55.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Needham & Company LLC restated a “buy” rating and issued a $62.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, May 10th. Finally, Citigroup reduced their target price on Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, May 10th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.11.

Check Out Our Latest Analysis on Xenon Pharmaceuticals

Xenon Pharmaceuticals Trading Down 0.3 %

NASDAQ XENE traded down $0.13 during trading hours on Wednesday, hitting $40.45. The company’s stock had a trading volume of 355,417 shares, compared to its average volume of 388,264. Xenon Pharmaceuticals Inc. has a 52 week low of $27.99 and a 52 week high of $50.99. The company has a market capitalization of $3.05 billion, a PE ratio of -14.93 and a beta of 1.19. The company’s 50-day simple moving average is $42.53 and its two-hundred day simple moving average is $41.83.

Xenon Pharmaceuticals (NASDAQ:XENEGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.07. The business had revenue of $1.00 million during the quarter. During the same quarter last year, the firm posted ($0.63) earnings per share. The business’s quarterly revenue was up .0% compared to the same quarter last year. Research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.01 EPS for the current fiscal year.

Xenon Pharmaceuticals Profile

(Free Report)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

Featured Stories

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENEFree Report).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.